ProPhase Labs Inc (NASDAQ:PRPH) — Market Cap & Net Worth
Market Cap & Net Worth: ProPhase Labs Inc (PRPH)
ProPhase Labs Inc (NASDAQ:PRPH) has a market capitalization of $207.48K ($207.48K) as of August 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31186 globally and #6212 in its home market, demonstrating a -25.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProPhase Labs Inc's stock price $0.04 by its total outstanding shares 4737007 (4.74 Million). See ProPhase Labs Inc (PRPH) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
ProPhase Labs Inc Market Cap History: 2015 to 2026
ProPhase Labs Inc's market capitalization history from 2015 to 2026. Data shows change from $3.01 Million to $207.48K (-22.49% CAGR).
Index Memberships
ProPhase Labs Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.48 Trillion | 0.00% | #922 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #2903 of 3165 |
Weight: ProPhase Labs Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProPhase Labs Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProPhase Labs Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.53x
ProPhase Labs Inc's market cap is 0.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.01 Million | $20.60 Million | -$3.60 Million | 0.15x | N/A |
| 2016 | $4.01 Million | $21.01 Million | -$2.87 Million | 0.19x | N/A |
| 2017 | $4.35 Million | $9.87 Million | $41.83 Million | 0.44x | 0.10x |
| 2018 | $10.75 Million | $13.13 Million | -$1.74 Million | 0.82x | N/A |
| 2019 | $8.19 Million | $9.88 Million | -$3.15 Million | 0.83x | N/A |
| 2020 | $38.15 Million | $14.51 Million | -$2.12 Million | 2.63x | N/A |
| 2021 | $31.27 Million | $79.04 Million | $6.27 Million | 0.40x | 4.99x |
| 2022 | $45.62 Million | $122.65 Million | $18.46 Million | 0.37x | 2.47x |
| 2023 | $21.41 Million | $44.38 Million | -$16.78 Million | 0.48x | N/A |
| 2024 | $3.59 Million | $6.77 Million | -$53.36 Million | 0.53x | N/A |
Competitor Companies of PRPH by Market Capitalization
Companies near ProPhase Labs Inc in the global market cap rankings as of August 7, 2026.
Key companies related to ProPhase Labs Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $217.10 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #165 globally with a market cap of $141.03 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #498 globally with a market cap of $53.38 Billion USD ( CN¥364.81 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #622 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $217.10 Billion | $577.83 |
| #165 | Danaher Corporation | NYSE:DHR | $141.03 Billion | $199.66 |
| #498 | WuXi AppTec Co Ltd | SHG:603259 | $53.38 Billion | CN¥147.50 |
| #622 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $584.78 |
ProPhase Labs Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, ProPhase Labs Inc's market cap moved from $3.01 Million to $ 207.48K, with a yearly change of -22.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $207.48K | -90.21% |
| 2025 | $2.12 Million | -40.89% |
| 2024 | $3.59 Million | -83.25% |
| 2023 | $21.41 Million | -53.06% |
| 2022 | $45.62 Million | +45.87% |
| 2021 | $31.27 Million | -18.04% |
| 2020 | $38.15 Million | +366.00% |
| 2019 | $8.19 Million | -23.83% |
| 2018 | $10.75 Million | +147.03% |
| 2017 | $4.35 Million | +8.49% |
| 2016 | $4.01 Million | +33.34% |
| 2015 | $3.01 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of ProPhase Labs Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $207.48K USD |
| MoneyControl | $207.48K USD |
| MarketWatch | $207.48K USD |
| marketcap.company | $207.48K USD |
| Reuters | $207.48K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more